Wolverine Legal Status, FDA 503A Category, and Compounding Access

Wolverine legal status: where access stands, and where it is heading

The headline on the Wolverine legal status board is momentum, anchored to a scheduled fact. Access to Wolverine's components through compounding pharmacies is under active FDA review, and the question of whether these peptides may be used in 503A compounding is on a public agenda. An FDA Pharmacy Compounding Advisory Committee (PCAC) meeting is scheduled for July 23-24, 2026 to discuss these peptides as candidates for the 503A bulk drug substances list ^[13]. That is a scheduled evaluation, and it is the clearest signal that the regulatory picture is being looked at rather than left static.

That momentum sits on top of a present-tense fact that has not changed. On the FDA page dated April 22, 2026, BPC-157 and TB-500 appear under "Bulk drug substances nominated but withdrawn," with the agency's safety concerns still shown for each ^[11]. FDA placed both in Category 2 effective with the September 29, 2023 update to its list of nominated bulk substances ^[11]. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, so compounding-pharmacy access to these peptides is currently restricted ^[12].

Nothing here states that any reclassification has occurred, been dated, or been decided. A PCAC discussion is advisory; it is a step in evaluation, not a listing decision ^[12][13]. Access may expand in 2026 — that is a possibility tied to a scheduled review, not an outcome. This page reads the record as it currently stands and posts the scheduled meeting as exactly what it is: a date on the calendar, not a decision on the books.

What "Category 2" means under the 503A framework

Drug compounding in the United States is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and licensed physicians, pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[12].

A compounder may use a bulk drug substance — an active ingredient used as a starting material rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet on a bulks list are evaluated through a public nomination process with input from PCAC ^[12].

FDA's interim policy sorted nominated substances into categories. Category 1 substances may be eligible for the bulks list, were nominated with sufficient supporting information, and do not raise significant safety risks; FDA stated it does not intend to act against a compounder using a Category 1 substance while evaluation continues ^[12]. Category 2 substances were nominated with sufficient information to evaluate but were identified by FDA as raising significant safety risks; they are not covered by that enforcement-discretion policy, and FDA stated it would consider taking action against a compounder using one ^[12]. The current FDA page says both Wolverine nominations were withdrawn and the ingredients are no longer in Category 2 ^[11].

Both components are on the same scheduled FDA agenda

There is no component carve-out in Wolverine. Neither peptide appears in FDA's current Category 2 table because the sponsors withdrew both nominations. FDA's public calendar lists BPC-157 (entered as "BPC-157 (free base)" / "BPC-157 acetate") and TB-500 (entered as "TB-500 (free base)" / "TB-500 acetate," the LKKTETQ fragment FDA associates with Thymosin Beta-4) as bulk drug substances being considered for inclusion on the 503A bulks list at the July 23-24, 2026 PCAC meeting ^[13].

FDA's withdrawn-nomination entry for the TB-500 leg reads "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," and keeps the concerns about potential immunogenicity for certain routes of administration and a lack of important safety information ^[11]. The BPC-157 entry cites concerns including potential immunogenicity for certain routes and complexities with peptide-related impurities and active-ingredient characterization ^[11].

Being discussed by PCAC is a step in evaluation, not a final listing decision ^[12]. The outcome of the July 2026 meeting is not knowable in advance and is not stated here. Today's FDA record shows both nominations were pulled; staff proposed against listing the two ingredients before the July 2026 meeting, and the agency had posted no account of the committee's votes as of September 2026.

How legally compounded peptide access works

In general terms, a legally compounded medication in the United States is prepared only after a defined pathway is followed. A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate. Telehealth can serve as the front-end channel for that evaluation, but it does not change which substances are eligible to be compounded and does not remove the need for a legitimate prescriber-patient relationship and a valid prescription ^[12].

If appropriate and lawful, the prescriber issues a valid, patient-specific prescription. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger office or batch use, sourced from an FDA-registered 503B outsourcing facility ^[12].

The ingredient-eligibility caveat governs all of this. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. Ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands — which is the present-tense situation for both Wolverine components ^[11][12]. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to supply any substance.

Both components are WADA-prohibited

Beyond the compounding question, both Wolverine components are prohibited in sport. The World Anti-Doping Agency prohibits BPC-157 under its S0 non-approved-substances category, and TB-500 / Thymosin Beta-4 falls under prohibited peptide, growth-factor, and tissue-repair categories ^[14]. The blend is therefore banned for the relevant classes both in and out of competition. None of this is an FDA approval status — WADA prohibition and FDA compounding category are separate questions, and neither makes the blend an approved medicine.

Frequently asked: regulatory and access questions

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is an FDA-approved drug, and both are prohibited by WADA ^[11][14]. The current FDA page records the nominations for BPC-157 and TB-500 as withdrawn while retaining its safety concerns, and has not explained how a 503A pharmacy should handle that status ^[11][12]. WADA bans BPC-157 (S0) and TB-500 / Thymosin Beta-4 in and out of competition ^[14].

Is Wolverine legal?

Neither Wolverine component has FDA approval; the agency records both nominations as withdrawn and has not stated what that status means for a pharmacy ^[11][12]. Both peptides are on a scheduled July 23-24, 2026 FDA advisory-committee agenda for evaluation as 503A bulks-list candidates — a scheduled discussion, not a decision ^[13]. Both are also WADA-prohibited ^[14]. This is general information, not legal advice.

Can you get BPC-157 from a compounding pharmacy?

Not through routine 503A compounding while its current status stands. FDA's table says the nomination for BPC-157 was withdrawn, so the ingredient is no longer in Category 2; the agency has not explained whether a 503A pharmacy may prepare it ^[11][12]. Lawful compounded access generally requires a licensed-prescriber evaluation and a valid prescription, and is constrained by whether the ingredient is eligible under the 503A/503B rules ^[12].

What is the FDA 503A status of Wolverine?

Both of Wolverine's components are 503A Category 2 — bulk drug substances FDA identified as possibly presenting significant safety risks, effective the September 29, 2023 list update ^[11]. Both BPC-157 and TB-500 appear on the July 23-24, 2026 PCAC agenda as candidates being considered for the 503A bulks list, which is a scheduled evaluation rather than a change in current status ^[13].